FRENCH SCIENCE SEMINAR

The French Office for Science and Technology and the West Wireless Health Institute invite you to listen to Dr. Philip Low on June 24th, 7:00pm at the West Wireless Health Institute

Presentation in English

PHILIP LOW, Ph.D.

*Founder, Chairman & CEO, NeuroVigil, Inc.
*Adjunct Professor, Stanford School of Medicine
*Visiting Professor, Massachusetts Institute of Technology
*Research Affiliate, The Salk Institute for Biological Studies

Severe neuropathologies are usually diagnosed after significant, largely irreversible brain damage has already occurred. Dr. Low's goal is for people to reliably have access to their own brain health in real time, well in advance of the onset of cognitive symptoms. To this end, he has developed groundbreaking computational techniques, inspired by Pointillist paintings, which do not require data from loud and costly brain scanners or multichannel electrode arrays which restrict a person's overall ability to freely interact with the world. Instead, these algorithms allow for a rapid quantification, analysis, and classification of data from a single channel of electroencephalogram (EEG); obviate the need for manual analysis; and use the dynamic range of sleep EEGs as a window into brain activity.

These new techniques have made possible the identification of known brain patterns in unexpected places, such as in birds, as well as novel brain patterns in humans including a novel human sleep state. Dr. Low will discuss these findings and cover new approaches NeuroVigil has developed to dramatically simplify the collection of single-channel data in humans and other species, including the iBrain, enabling widespread comparative analysis of neural activity as well as early testing of novel pharmaceutical drugs.

For a recent overview of Dr. Low’s work and NeuroVigil, please follow this link

Dr. Philip Steven Low did his PhD at the Salk Institute, which he joined on the recommendation of the late Francis Crick, Nobel Laureate of DNA fame, after completing his undergraduate degree at University of Chicago where he studied Mathematics, Neuroscience, and Physics and invented novel neurosurgical techniques undermining the role Neuroscientists have attributed to the Neocortex. At Harvard Medical School, Dr. Low showed that compound H, a collagen Type I Inhibitor, could successfully neutralize the growth of fibroid tumors. At the Salk, Dr. Low invented the SPEARS algorithm and authored one of the shortest PhD theses on record: "A New Way To Look At Sleep: Separation & Convergence," a one-page solution to a longstanding problem in brainwave analysis. The experimental and computational methods Dr. Low has developed challenge our understanding of brainwaves during sleeping and awake states in humans and across species. His work has been featured in technical and popular articles including including CNN, The MIT Technology Review, The Huffington Post, The New Scientist, The Economist, The New York Times, etc. and has garnered awards from the National Science Foundation, Merck Co., The Ray Thomas Edwards and Kavli Foundations for Innovative Research, as well as five awards from the Sloan and Swartz Foundations, and an extraordinary ability recognition in the field of brain signal detection from the United States Government.

To bring his innovations to the market, Dr. Low founded NeuroVigil, Inc., an award-winning Wireless Neurodiagnostics company comprising several Nobel laureates and founders of Fortune 500 companies. The company, which develops the iBrain, a wireless iPod for the brain, and assists many of the world’s top pharmaceutical companies with outpatient drug evaluations, won the 2008 annual Draper Fisher Jurvetson 250K Venture Challenge, the UCSD50K Entrepreneurship Competition and delivered the IN3 MedTech Investment in Medicine Summit Keynote Address back-to-back. The company is backed by some of the world’s savviest entrepreneurs, including QUALCOMM’S Dr. Irwin Jacobs.

Dr. Low is the Founder and President of the highly successful 1st International Congress on Alzheimer's Disease & Advanced Neurotechnologies, which was held in Monaco in Feb. 2010.